Heghine Khachatryan: Emerging Evidence Links NET Formation to Thrombosis and Disease Progression in Gynecologic Malignancies
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared
Jim Hoffman’s post on LinkedIn:
“NETosis and Thrombosis in Gynecologic Malignancies: An Emerging Link Between Inflammation and Cancer.
Neutrophil extracellular traps (NETs) have emerged as key mediators at the intersection of inflammation, malignancy, and thrombosis.
In gynecologic cancers, NETosis contributes not only to tumor progression, metastatic dissemination, and therapeutic resistance but also plays a pivotal role in the pathogenesis of cancer-associated thrombosis.
NETs provide a highly prothrombotic scaffold that promotes platelet activation, endothelial dysfunction, and coagulation cascade amplification, thereby increasing the risk of venous thromboembolism (VTE).
Growing evidence suggests that elevated NET formation in ovarian, endometrial, and cervical cancers correlates with more aggressive disease phenotypes, poorer clinical outcomes, and a heightened thrombotic burden.
Beyond their pathogenic role, NET-associated biomarkers are increasingly being investigated as potential tools for risk stratification, disease monitoring, and the development of targeted therapeutic strategies.
As our understanding evolves, NETosis is becoming recognized as a critical mechanistic bridge linking cancer, inflammation, and thrombosis.
Targeting NET formation may represent a promising future approach for reducing both tumor progression and thrombotic complications in patients with gynecologic malignancies.”
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared a post on LinkedIn about a recent article by Naina Kumar, published in Clinical and Translational Oncology, adding:
“NETs exhibit a dual role in gynecological cancers, contributing to tumor progression and therapy resistance while also presenting valuable diagnostic and therapeutic opportunities.
Their components—NE, MPO, CitH3, cfDNA, and ctDNA are emerging as promising biomarkers for disease monitoring and prognosis.
Targeting NETs through DNase therapy, PAD4 inhibition, ROS modulation, or immune regulation holds potential to enhance treatment efficacy and support personalized management of gynecological cancers.”
Title: Neutrophil extracellular traps (NETosis) in gynecologic cancers: from pathogenesis to therapeutic opportunities: a narrative review
Authors: Naina Kumar
Stay updated on all scientific advances Hemostasis Today.
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event
-
Sep 25, 2026, 05:47Omid Seidizadeh: Evolutionary Constraint and Population Variation Across Coagulation Genes
-
Sep 25, 2026, 05:40Gerald Bertrand: Presenting UMi-NGS Non-Invasive Foetal HPA Genotyping at DGTI 2026
-
Sep 25, 2026, 05:33Urge Congress to support the Sickle Cell Disease Comprehensive Care Act – ASH
-
Sep 25, 2026, 05:24Isabelle Mahé: Reduced-Dose Apixaban in Extended CAT Treatment
-
Sep 25, 2026, 05:15Maria Cherska: High Cholesterol Isn’t Always Diet or Lifestyle – Sometimes It’s Genetic
-
Sep 25, 2026, 05:07Nancy Braithwaite: BBTS Specialist Certificate in Transfusion Science Practice
-
Sep 24, 2026, 18:43Hugh Nguyen: Honored to Accept the Friend of Singapore Red Cross Award
-
Sep 24, 2026, 18:42Titilope Fasipe: Proud to Support American Society of Hematology’s SCD Initiative